Cargando…
BSD2000深部热疗联合PT方案化疗在非小细胞肺癌中的应用
BACKGROUND AND OBJECTIVE: The aim of this study is to determine the short-term efficacy, toxicity and the rate of life-quality improvement of BSD2000 deep hyperthermia combined with chemotherapy of PT regimen in patients with non-small cell lung cancer (NSCLC) by comparation with PT regimen alone. M...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000516/ https://www.ncbi.nlm.nih.gov/pubmed/20673506 http://dx.doi.org/10.3779/j.issn.1009-3419.2010.02.10 |
Sumario: | BACKGROUND AND OBJECTIVE: The aim of this study is to determine the short-term efficacy, toxicity and the rate of life-quality improvement of BSD2000 deep hyperthermia combined with chemotherapy of PT regimen in patients with non-small cell lung cancer (NSCLC) by comparation with PT regimen alone. METHODS: Sixty patients with NSCLC were randomly divided into the treatment group and control group, with 30 each.The treatment group was treated with chemotherapy (paclitaxel:135mg/m2 ivdirp 3 h qd d1+cisplatin:20 mg/m(2) ivdirp qd d1-5) in combination with BSD2000 deep hyperthermia, and hyperthermia was positioned precisely and maintained for 60 min (2 times a cycle:d1, 4 after the end of chemotherapy within two hours).The control group was treated with chemotherapy alone.Treatment response in both groups were evaluated as well as side-effects after 3 cycles.By observing the results, comparing response rate, toxic side effects and quality of life improvement rate in two groups. RESULTS: The efficiency and the rate of life-quality improvement in the treatment group were 63.33%, 76.67% respectively, and 36.67%, 40.00% in the control group respectively.There were significant differences between two groups (P < 0.05).The main side-effects were myelosuppression and gastrointestinal reactions, no significant difference between two groups (P > 0.05). CONCLUSION: BSD2000 deep hyperthermia combined with chemotherapy in patients with NSCLC can significantly increase the efficacy, response rate and quality of life improvement and without increasing sideeffects compared to chemotherapy alone. |
---|